Immune Activation Anti-Cancer Antiviral Gut Health Metabolic Patents
Home›Topics› Antiviral Research
Research Topic

Antiviral Research

How Aureobasidium pullulans beta glucan primes antiviral immunity: ISG upregulation, interferon pathways, NK cell activation, and influenza prevention studies.

20+ Studies ISG Upregulation Documented Influenza Prevention (In Vivo) COVID-19 Pathway Research
Direct Answer

Aureobasidium pullulans beta glucan primes antiviral immunity through two mechanisms: (1) a Dectin-1-independent pathway that upregulates interferon-stimulated genes (ISGs) including OAS1, MX1, and IFIT1, and (2) NK cell activation via CR3 that enhances killing of virus-infected cells. Animal studies document prevention of influenza-related mortality. These are immune mechanism findings — not claims that beta glucan treats or prevents specific viral infections.

Antiviral Mechanisms

How Beta Glucan Primes Antiviral Immunity

Two distinct pathways contribute to the antiviral immune effects documented in Aureobasidium beta glucan research.

ISG Upregulation (Dectin-1 Independent)

Beta glucan upregulates interferon-stimulated genes (ISGs) in macrophages through a pathway independent of Dectin-1. ISGs encode proteins with antiviral functions including viral RNA sensors, restriction factors, and immune amplifiers. This pathway does not require prior viral exposure — it primes cells before infection.

OAS1
MX1
IFIT1
IFIT2
ISG15
RSAD2
NK Cell Killing of Virus-Infected Cells

NK cells activated by beta glucan via CR3 receptors have enhanced capacity to recognize and destroy virus-infected cells. Virus-infected cells downregulate MHC class I — a signal NK cells use to identify targets. CR3-primed NK cells show increased perforin release against infected cell lines in vitro.

Type I Interferon Pathway

Beta glucan triggers production of Type I interferons (IFN-α/β) which signal neighboring cells to upregulate antiviral defenses — creating an “antiviral state” in surrounding tissue. This bystander protection mechanism amplifies the initial immune response.

Innate Immune Priming

Unlike vaccines that target specific pathogens, beta glucan-mediated immune priming is non-specific — it enhances general innate immune readiness. This “trained immunity” concept is particularly relevant in the context of novel pathogens where adaptive immune memory is absent.

Key Studies

Landmark Antiviral Research

Selected peer-reviewed studies on Aureobasidium pullulans beta glucan and antiviral immunity.

In Vitro
In Vitro: Dectin-1-Independent ISG Upregulation in Human Macrophages
Beta glucan treatment upregulated OAS1, MX1, IFIT1, and IFIT2 expression in human macrophages. Dectin-1 knockout cells retained ISG upregulation, confirming a Dectin-1-independent pathway. Type I interferon signaling identified as the mediator.
Antiviral Research · DOI-verified
In Vivo
In Vivo: Oral Beta Glucan and Influenza-Associated Mortality in Mice
Mice receiving oral Aureobasidium beta glucan prior to influenza A challenge showed significantly reduced mortality compared to untreated controls. NK cell depletion eliminated the protective effect, confirming an NK-dependent mechanism.
Journal of Infectious Diseases · DOI-verified
In Vitro
In Vitro: SARS-CoV-2 Relevant Immune Pathway Activation
Beta glucan upregulated ACE2 pathway modulators and ISGs relevant to SARS-CoV-2 defense in human monocyte-derived macrophages. Authors proposed beta glucan as candidate for immune-priming studies in COVID-19 context.
Frontiers in Immunology · DOI-verified
Review
Review: Beta Glucan and Antiviral Immunity — Mechanisms and Evidence
Systematic review covering ISG upregulation, NK cell antiviral activity, and interferon pathway mechanisms. Concluded that β-1,3/1,6-glucan (including Aureobasidium-derived) represents the most immunologically active structural type for antiviral priming.
Nutrients · DOI-verified · PMID indexed
View All Antiviral Studies
Common Questions

Antiviral FAQ

Research documents antiviral immune priming via ISG upregulation (OAS1, MX1, IFIT1) through a Dectin-1-independent pathway, and NK cell activation via CR3 for killing virus-infected cells. Animal studies show influenza prevention. These are mechanism findings — not claims of treating or preventing specific viral infections.
Studies have investigated antiviral pathways relevant to SARS-CoV-2 including ISG upregulation and interferon signaling in macrophages. No completed clinical trials in COVID-19 patients have been published. Beta glucan is not a treatment for COVID-19.
A pathway where beta glucan upregulates interferon-stimulated genes (ISGs) in macrophages without requiring Dectin-1 receptor involvement. ISGs encode antiviral proteins (OAS1, MX1, IFIT1) that create an “antiviral state” in immune cells. Confirmed by studies showing ISG upregulation in Dectin-1 knockout cells treated with beta glucan.
No. Vaccines train the adaptive immune system to recognize specific pathogens. Beta glucan activates innate immunity non-specifically — it doesn’t create pathogen-specific memory. The two mechanisms are complementary, not interchangeable. Beta glucan is not a substitute for vaccination.
Research findings only. Beta glucan is not approved to treat, prevent, or cure any viral infection. Consult a physician for medical decisions.

Browse All Antiviral Studies

20+ indexed studies with abstracts, AI summaries, DOI links, and PMID references.

Open Research Archive